Introduction to biostatistics: Part 2. Measures of association as used to address therapy, harm, and etiology questions

Carney, Stuart; Doll, Helen
September 2005
ACP Journal Club;Sep/Oct2005, Vol. 143 Issue 2, pA8
Academic Journal
Discusses the measures of association in clinical studies. Strength of the relation between an exposure and an outcome in clinical studies; Use of the measures of association in random clinical trials and cohort studies; Comparison of effects of streptomycin and placebo.


Related Articles

  • Indirect and mixed treatment comparisons in arthritis research. Ades, Anthony E.; Madan, Jason; Welton, Nicky J. // Rheumatology;Sep2011 Supplement 4, Vol. 50 Issue suppl_4, piv5 

    Evidence for the efficacy of biologic therapies in inflammatory arthritis comes overwhelmingly from placebo-controlled trials. Increasingly, however, authorities responsible for purchasing and re-imbursement have tried to determine whether there are differences between these powerful new...

  • Unique Considerations in the Evaluation of Antibacterials in Clinical Trials for Pediatric Community-Acquired Pneumonia. Bradley, John S.; McCracken, George H. // Clinical Infectious Diseases;12/1/2008 Supplement 3, Vol. 47, pS241 

    There are few placebo-controlled, randomized, prospective clinical trials of antibiotic therapy for community- acquired pneumonia (CAP) in children. The reduction in mortality seen in early trials of antibacterials for treatment of bacterial CAP in adults and children was dramatic and led to the...

  • Position Paper: Recommended Design Features of Future Clinical Trials of Antibacterial Agents for Community-Acquired Pneumonia.  // Clinical Infectious Diseases;12/1/2008 Supplement 3, Vol. 47, pS249 

    The article presents the recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia (CAP). The efficaciousness of new antibiotics for the treatment of CAP has been assessed and compared with that of established antibiotics in noninferiority...

  • Different Placebos, Different Mechanisms, Different Outcomes: Lessons for Clinical Trials. Benedetti, Fabrizio; Dogue, Sara // PLoS ONE;11/4/2015, Vol. 10 Issue 10, p1 

    Clinical trials use placebos with the assumption that they are inert, thus all placebos are considered to be equal. Here we show that this assumption is wrong and that different placebo procedures are associated to different therapeutic rituals which, in turn, trigger different mechanisms and...

  • The Qure study: Q fever fatigue syndrome - response to treatment; a randomized placebo-controlled trial. Keijmel, Stephan P.; Delsing, Corine E.; Sprong, Tom; Bleijenberg, Gijs; Van der Meer, Jos W. M.; Knoop, Hans; Bleeker-Rovers, Chantal P. // BMC Infectious Diseases;2013, Vol. 13 Issue 1, p1 

    Background: Q fever is a zoonosis that is present in many countries. Q fever fatigue syndrome (QFS) is one of the most frequent sequelae after an acute Q fever infection. QFS is characterized by persistent fatigue following an acute Q fever infection, leading to substantial morbidity and a high...

  • Is C-reactive protein testing useful to predict outcome in patients with acute bronchitis? Llor, Carl; Plana-Ripoll, Oleguer; Moragas, Ana; Bayona, Carolina; Morros, Rosa; Pera, Helena; Miravitlles, Marc // Family Practice;Oct2014, Vol. 31 Issue 5, p530 

    Background. A recent clinical trial could not find differences between anti-inflammatory drugs, antibiotics and placebo in shortening the duration of symptoms in acute bronchitis. Objectives. To investigate if C-reactive protein (CRP) concentrations at presentation are predictive of symptom...

  • Clinical trial design in systemic lupus erythematosus: lessons learned and future directions. Strand, V. // Lupus;2004, Vol. 13 Issue 5, p406 

    Designing successful randomized controlled trials (RCTs) in systemic lupus erythematosus (SLE) poses many challenges. It remains difficult to correlate alterations in biologic markers with clinical outcome, especially when signs and symptoms are intermittent and broadly variable between...

  • How can we increase the quality and value of clinical research? Corey, Jacquelynne P.; Reidy, Patrick M. // ENT: Ear, Nose & Throat Journal;Dec2004, Vol. 83 Issue 12, p796 

    Focuses on improving the quality and value of clinical research in otology. Difference of clinical research from basic science research; Editorials and subspecialty guidelines that have been written regarding the relevance and importance of the use of outcomes research instruments for clinical...

  • Randomized trials for the real world: making as few and as reasonable assumptions as possible. Baker, Stuart G.; Kramer, Barnett S. // Statistical Methods in Medical Research;Jun2008, Vol. 17 Issue 3, p243 

    The strength of the randomized trial to yield conclusions not dependent on assumptions applies only in an ideal setting. In the real world various complications such as loss-to-follow-up, missing outcomes, noncompliance and nonrandom selection into a trial force a reliance on assumptions. To...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics